troglitazone has been researched along with Acute Myelogenous Leukemia in 2 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Torii, I | 1 |
| Morikawa, S | 1 |
| Nakano, A | 1 |
| Morikawa, K | 1 |
| Gu, C | 1 |
| Ye, T | 1 |
| Wells, RA | 1 |
2 other studies available for troglitazone and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Establishment of a human preadipose cell line, HPB-AML-I: refractory to PPARgamma-mediated adipogenic stimulation.
Topics: Adipocytes; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antineo | 2003 |
Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Cytarabine; Daunorubicin; | 2006 |